ESSA Pharma (NASDAQ:EPIX) Stock Price Crosses Above 50-Day Moving Average of $5.44

ESSA Pharma Inc. (NASDAQ:EPIX) (TSE:EPI)’s stock price crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $5.44 and traded as high as $6.85. ESSA Pharma shares last traded at $6.05, with a volume of 181,690 shares trading hands.

ESSA Pharma Price Performance

The stock has a market capitalization of $268.40 million, a P/E ratio of -9.60 and a beta of 1.84. The firm’s 50 day moving average price is $5.44 and its 200 day moving average price is $6.31.

ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) last issued its quarterly earnings data on Monday, August 5th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.10. On average, equities research analysts forecast that ESSA Pharma Inc. will post -0.71 earnings per share for the current year.

Hedge Funds Weigh In On ESSA Pharma

Several hedge funds and other institutional investors have recently modified their holdings of the company. RTW Investments LP bought a new position in shares of ESSA Pharma during the fourth quarter valued at about $15,171,000. Janus Henderson Group PLC raised its stake in ESSA Pharma by 7.9% in the first quarter. Janus Henderson Group PLC now owns 1,175,242 shares of the company’s stock worth $9,978,000 after buying an additional 85,760 shares in the last quarter. BNP Paribas Financial Markets raised its stake in ESSA Pharma by 164.9% in the fourth quarter. BNP Paribas Financial Markets now owns 57,466 shares of the company’s stock worth $379,000 after buying an additional 35,771 shares in the last quarter. Finally, EntryPoint Capital LLC bought a new position in ESSA Pharma in the first quarter worth about $38,000. 75.12% of the stock is owned by institutional investors.

ESSA Pharma Company Profile

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.